Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reversing Type 1 Diabetes After it is Established: A Pilot Safety and Feasibility Study of Anti-Thymocyte Globulin (Thymoglobulin®)and Pegylated GCSF (Neulasta®) in Established Type 1 Diabetes

NCT01106157 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT01106157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01106157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reversing Type 1 Diabetes After it is Established: A Pilot Safety and Feasibility Study of Anti-Thymocyte Globulin (Thymoglobulin®)and Pegylated GCSF (Neulasta®) in Established Type 1 Diabetes
Lead sponsor
University of Florida
Phase
Phase 1/2
Overall status
Completed
Start date
April 30, 2010
Completion date
July 16, 2019
Enrollment
25 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, type 1